Skip to content

Soluble Factors in the Serum of Severely Burned Patients

Soluble Factors in the Serum of Severely Burned Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02549079
Enrollment
23
Registered
2015-09-14
Start date
2004-01-31
Completion date
2008-12-31
Last updated
2015-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn Patients

Brief summary

The present study investigates the levels of certain soluble factors in the blood of patients with severe burn injury. Serum levels of different soluble factors will be correlated with the clinical outcome, presence of sepsis, the area of burn, and other clinical parameters in order to make a statement regarding their use as biomarkers in the prediction and monitoring of burn patients.

Detailed description

Burn patients still represent a critical patient collective with a high mortality rate although treatment technologies have improved over the years. One problem healthcare professionals face is the fact that reliable biomarker which predict the clinical outcome, the onset of sepsis, and monitor the severity of disease in burn patients are still missing. These biomarkers would allow an early adoption of treatment modalities to improve the outcome and prevent life-threatening complications. Blood samples from severely burned patients will be collected over a period of five days and different cytokines (for example the macrophage migration inhibitory factor protein family) will be measured in the serum. Clinical data of the patients (sepsis, total body surface area of burns, abbreviated burn severity index, sepsis-related organ failure assessment, etc.) will be documented and correlated to the levels of soluble factors.

Interventions

OTHERBlood sample

Blood will be taken from all patients meeting the inclusion criteria.

Sponsors

RWTH Aachen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age * minimum of 10% total body surface area burn * needing ICU treatment

Exclusion criteria

* younger than 18 years of age * immunosuppression (e.g. HIV) * undergone surgery 2 weeks prior to burn injury * malignancies * severe diseases (myocardial infarction, lung embolism) * declining to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Survival of a total of 23 burn patients during their treatment in the ICUfive daysPatients will be monitored over five days and death (with underlying condition, time) will be determined and documented by medical doctors.

Secondary

MeasureTime frameDescription
Onset of sepsis of a total of 23 burn patients during their treatment in the ICUfive daysOnset of systemic inflammatory response syndrome, sepsis, septic shock will be monitored by medical doctors by standardized assessment of clinical parameters according to the consensus of the American College of Chest Physicians (ACCP) and the Society of Critical Care Medicine (SCCM) (released in Critical Care Med, 20(6):864-74, 1992, Pubmed ID: 1597042)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026